Back to Search
Start Over
HCV and the hepatic lipid pathway as a potential treatment target
- Source :
- Journal of Hepatology. (6):1428-1440
- Publisher :
- European Association for the Study of the Liver. Published by Elsevier B.V.
-
Abstract
- Atherosclerosis has been described as a liver disease of the heart [1]. The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus-host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3]. One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: • update the hepatologist on lipid metabolism • review the evidence that HCV exploits hepatic lipid pathways to its advantage • discuss approaches to targeting host lipid pathways as adjunctive therapy.
- Subjects :
- Very low-density lipoprotein
Lipoproteins
Hepacivirus
Type 2 diabetes
Disease
Lipoproteins, VLDL
Models, Biological
chemistry.chemical_compound
Liver disease
Apolipoproteins E
Immune system
Chylomicrons
Humans
Medicine
Apolipoproteins A
Triglycerides
Apolipoproteins B
Hypolipidemic Agents
Hepatology
business.industry
Cholesterol
Lipid metabolism
Hepatitis C
A300
Lipid Metabolism
medicine.disease
Antiviral agents
Liver
chemistry
Immunology
lipids (amino acids, peptides, and proteins)
business
Metabolic Networks and Pathways
Subjects
Details
- Language :
- English
- ISSN :
- 01688278
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Journal of Hepatology
- Accession number :
- edsair.doi.dedup.....de94d87f5d7581dbe0ea0d52d009f265
- Full Text :
- https://doi.org/10.1016/j.jhep.2011.06.004